Plexium
Plexium, a San Diego-based med-tech firm, pioneers first-in-class therapeutics via E3 ligases modulation.
Founded
2018Plexium, a San Diego-based med-tech firm, pioneers first-in-class therapeutics via E3 ligases modulation.
Plexium, founded in San Diego, California, is a leading medical technology company focused on developing first-in-class therapeutics by modulating E3 ligases. The company's core mission is to push the boundaries of targeted protein degradation (TPD) to improve lives. Plexium offers a comprehensive TPD platform powered by proprietary high-throughput cell-based screening (uHTS) technology, enabling the rational design and discovery of monovalent protein degraders across various modalities. Their market focus includes addressing unmet medical needs through innovative pharmaceutical solutions.
Notable affiliated individuals include experienced scientists and industry leaders who drive Plexium's pioneering research and development efforts. The company has attracted significant investment from prominent venture capital firms, underscoring confidence in its groundbreaking approach. Key achievements include the successful development of their TPD platform and the advancement of multiple therapeutic candidates. Overall, Plexium's impact lies in its potential to revolutionize the treatment landscape for various diseases through targeted protein degradation.
Companies similar to Plexium include Neomorph, Nurix, Differentiated Therapeutics and Biotheryx.
Plexium was founded in 2018.
Plexium's headquarters is located in San Diego, CA, US.
Plexium's most recent funding round was for $102M (USD) in February 2022.
As of Feb 23, 2022, Plexium has raised a total of $165M (USD).
Plexium has 94 employees as of Feb 4, 2024.
Differentiated Therapeutics
dxtherapeutics.com
